Antimicrobial activity of an antimicrobial peptide against amastigote forms of Leishmania major

سال انتشار: 1397
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 44

فایل این مقاله در 6 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

JR_VRFAN-9-4_005

تاریخ نمایه سازی: 25 آبان 1402

چکیده مقاله:

Zoonotic cutaneous leishmaniasis caused by Leishmania major is a most common type of vector-borne disease in Iran. The pentavalent antimonial drugs have been used in the treatment of cutaneous leishmaniasis for a long time, but drug resistance and some of serious side effects have been reported. Thus, discovery and development of new therapeutic candidates are needed. The CM۱۱ peptide is one of these peptides that its anti-bacterial activity has been proven. This peptide is a short cecropin–melittin hybrid peptide obtained through a sequence combination approach. The aim of this study was to evaluate in vitro anti-leishmanial activity of CM۱۱ peptide against amastigote forms of Leishmania major. In this study, amastigote forms of Iranian strain of L. major (MRHO/IR/۷۵/ER) were cultured in the presence of different concentrations of meglumine antimoniate (Glucantime®) to find the most appropriate in vitro concentration of Glucantime® against L. major amastigotes. Then, the anti-leishmanial activities of various concentrations of CM۱۱ peptide (۸, ۱۶, ۳۲ and ۶۴ µM) were evaluated for ۲۴, ۴۸ and ۷۲ hr by DAPI staining. In addition, MTT assay was used to determine the cytotoxic effects of CM۱۱ peptide on murine fibroblast cell line. The results showed that CM۱۱ peptide has antimicrobial activity against Iranian isolate of L. major in the laboratory conditions. It seems that the CM۱۱ peptide has significant potential to be used as a new anti-leishmanial agent.

کلیدواژه ها:

نویسندگان

Sara khalili

Department of Parasitology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran

Mehdi Mohebali

Department of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

Elaheh Ebrahimzadeh

Department of Parasitology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran

Parviz Shayan

Department of Parasitology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran

Samira Mohammadi-Yeganeh

Department of Biotechnology, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Mehrdad Moosazadeh Moghaddam

Applied Biotechnology Research Center, Baqiyatallah University of Medical Science, Tehran, Iran

Samira Elikaee

Department of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

Behnaz Akhoundi

Department of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

Mohammad Kazem Sharifi-Yazdi

Zoonosis Research Center, Tehran University of Medical Sciences, Tehran, Iran

مراجع و منابع این مقاله:

لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :
  • Brito ME, Andrade MS, Dantas-Torres F, et al. Cutaneous leishmaniasis ...
  • Aoun K, Bouratbine A. Cutaneous leishmaniasis in North Africa: A ...
  • Alvar J, Vélez ID, Bern C, et al. Leishmaniasis worldwide ...
  • Mohebali M, Javadian E, Yaghoobi Ershadi M, et al. Characterization ...
  • Shirzadi M, Esfahani S, Mohebali M, et al. Epidemiological status ...
  • Murray HW, Berman JD, Davies CR, et al. Advances in ...
  • Mohebali M, Fotouhi A, Hooshmand B, et al. Comparison of ...
  • Hadighi R, Mohebali M, Boucher P, et al. Un-responsiveness to ...
  • Zarean M, Maraghi S, Hajjaran H, et al. Comparison of ...
  • Hancock RE, Sahl HG. Antimicrobial and host-defense peptides as new ...
  • Cotter PD, Hill C, Ross RP. Bacteriocins: Developing innate immunity ...
  • Thevissen K, Kristensen HH, Thomma BP, et al. Therapeutic potential ...
  • Slocinska M, Marciniak P, Rosinski G. Insects antiviral and anticancer ...
  • Zhang L, Falla TJ. Host defense peptides for use as ...
  • Diaz-Achirica P, Ubach J, Guinea A, et al. The plasma ...
  • Luque-Ortega JR, Hof WV, Veerman EC, et al. Human antimicrobial ...
  • Vouldoukis I, Shai Y, Nicolas P, et al. Broad spectrum ...
  • Ferre R, Badosa E, Feliu L, et al. Inhibition of ...
  • Mohammadi-Azad Z, Moravej H, Fasihi-Ramandi M, et al. In vitro ...
  • Badosa E, Ferre R, Planas M, et al. A library ...
  • Mohebali M, Rezayat M, Gilani K, et al. Nanosilver in ...
  • Desjeux P. Leishmaniasis: Current situation and new perspectives. Comp Immunol ...
  • Ouellette M, Papadopoulou B. Mechanisms of drug resistance in Leishmania. ...
  • Handman E, Noormohammadi AH, Curtis JM, et al. Therapy of ...
  • Stober CB, Lange UG, Roberts MT, et al. From genome ...
  • Singh N, Kumar M, Singh RK. Leishmaniasis: Current status of ...
  • Cobb SL, Denny PW. Antimicrobial peptides for leishmaniasis. Curr Opin ...
  • Montesinos E. Antimicrobial peptides and plant disease control. FEMS Microbiol ...
  • Montesinos E, Bardaji E. Synthetic antimicrobial peptides as agricultural pesticides ...
  • Marcos JF, Munoz A, Perez-Paya E, et al. Identification and ...
  • Moghaddam MM, Abolhassani F, Babavalian H, et al. Comparison of ...
  • Moghaddam MM, Aghamollaei H, Kooshki H, et al. The development ...
  • Marr AK, Gooderham WJ, Hancock RE. Antibacterial peptides for therapeutic ...
  • Poorrajab F, Ardestani SK, Emami S, et al. Nitroimidazolyl-۱, ۳, ...
  • Ghaffarifar F. Leishmania major: In vitro and in vivo anti-leishmanial ...
  • Dolis D, Moreau C, Zachowski A, et al. Amino-phospholipid translocase ...
  • Rudenko SV, Wajdi KJM. Modulatory effect of peptide structure and ...
  • نمایش کامل مراجع